Sarepta Therapeutics Inc
SRPT
Market Cap$1.68B
Close$
$153.22
796% upside
Current Fair Value
796% upsideUndervalued by 796% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.68 Billion |
|---|---|
| Enterprise Value | $2.91 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $2.34 |
| Beta | 0.6 |
| Outstanding Shares | 97,362,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -6.71 |
|---|---|
| PEG | 0.5 |
| Price to Sales | 0.78 |
| Price to Book Ratio | 1.55 |
| Enterprise Value to Revenue | 1.3 |
| Enterprise Value to EBIT | -14.85 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.5 |
| Debt to Equity | 1.29 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Sarepta Therapeutics Inc
CEO: Douglas Ingram Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...